SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies ...
Investor's Business Daily on MSN1h
Inari Medical Catapults 30% On Rumored Stryker TakeoverShares of Inari Medical catapulted to a 12-month high Monday on a report medical devices maker Stryker is in advanced talks ...
A resident who lived across the hall from Hsia in the facility's memory care unit left her bleeding and unconscious on the ...
SciSparc has become one of the most talked-about stocks today, but what’s behind this unexpected surge? Let’s dive deep into what’s driving the action and how it compares to the broader market.
The Alzheimer’s Association is reminding those that winter weather conditions can be potentially dangerous and even ...
NDAQ:CMND) Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment ...
Analyst Sumant Kulkarni from Canaccord Genuity maintained a Buy rating on Bioxcel Therapeutics (BTAI – Research Report) and decreased the price ...
Patrick and Carol Webb had lived all over the world. Thirty years serving in the army, while Webb was gone, Carol took care ...
M&A didn’t return as hoped for in 2024. The biopharma industry is heading into the J.P. Morgan Healthcare Conference next ...
DSP-2342 is under clinical development by Sumitomo Pharma America and currently in Phase I for Unspecified Psychiatric Disorders.
Among significant news in a holiday spattered week, Dutch biotech argenx gained another approval in Japan for its Vyvdura ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback